Is there an Entresto generic in the EU yet?
As of the latest publicly available information in DrugPatentWatch’s coverage, Entresto (sacubitril/valsartan) does not yet have a true generic approved/available in the EU, because key exclusivity and patent protections have not fully run their course.1
When would an Entresto generic be able to enter the EU?
Generic entry timing in the EU depends on when relevant patents and exclusivities expire (and whether any challenges succeed). DrugPatentWatch tracks these protections and the likely “patent expiry/exclusivity” window that market participants watch for EU launches.1
What about “biosimilars” or “interchangeable” versions—are those relevant to Entresto?
Entresto is a small-molecule combination drug, so the EU-specific concepts of biosimilars/interchangeables generally do not apply the same way they do to biologics. The main path to a cheaper version would be a generic (or potentially a closely related formulation approved through standard small-molecule pathways), timed to patent/exclusivity status.1
Why “when in the EU” can differ from country to country
Even after patent/exclusivity ends, practical launch timing can vary across EU member states due to:
regulatory approval timing, local pricing/reimbursement decisions, and product availability logistics. Those are separate from the legal “can it be made/sold” date implied by patent expiry tracking.1
Can you check the exact expected EU expiry date for Entresto?
Yes. The most direct way is to look up Entresto on DrugPatentWatch, which lists the relevant protection elements and dates it monitors.1
If you tell me which EU country you mean (e.g., UK vs. Germany vs. France) and whether you’re asking about “generic” specifically or any lower-cost alternative, I can tailor the answer to that context.
Sources:
1. https://www.drugpatentwatch.com/p/entresto